Cencora
COR

$227.62

0.22%

Market Cap: 44.8B

About: Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Employees: 46,000

Healthcare Drugs, Proprietaries & Druggists Sundries

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 6 analysts

0

News positive %

of 8 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

140% more call options, than puts

Call options by funds: $1.59B | Put options by funds: $660M

57% more first-time investments, than exits

New positions opened: 168 | Existing positions closed: 107

38% more capital invested

Capital invested by funds: $34.5B [Q4 2023] → $47.6B (+$13.1B) [Q1 2024]

26% more funds holding in top 10

Funds holding in top 10: 19 [Q4 2023] → 24 (+5) [Q1 2024]

14.61% more ownership

Funds ownership: 83.85% [Q4 2023] → 98.46% (+14.61%) [Q1 2024]

6% more funds holding

Funds holding: 1,056 [Q4 2023] → 1,117 (+61) [Q1 2024]

6% less repeat investments, than reductions

Existing positions increased: 383 | Existing positions reduced: 407

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$224

2%

downside

Avg. target

$267

17%

upside

High target

$285

25%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

Baird David Rodgers	25%upside $285	Outperform Maintained	9 Jul 2024
Leerink Partners Michael Cherny	21%upside $275	Outperform Maintained	27 Jun 2024
Baird David Rodgers	22%upside $277	Outperform Maintained	2 May 2024
Citigroup Michael Rollins	23%upside $280	Buy Maintained	30 Apr 2024
Leerink Partners Michael Cherny	15%upside $261	Outperform Initiated	26 Feb 2024

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about COR published over the past 30 days

Zacks Investment Research

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

Zacks Investment Research

Why Cencora (COR) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Cencora (COR) is a Top Value Stock for the Long-Term

Zacks Investment Research

Why Cencora (COR) is Poised to Beat Earnings Estimates Again

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Cencora (COR) is Poised to Beat Earnings Estimates Again

The Highest Quality Dividend Growth Stocks In 2024

This article updates one I wrote in August 2022, which was based on a template article by David Van Knapp published in June 2020. I use an adapted quality scoring system to assess the quality of dividend growth stocks. The system employs six quality indicators from independent sources and assigns 0-5 points to each quality indicator, for a maximum of 30 points.

The Highest Quality Dividend Growth Stocks In 2024

Cencora Announces Date and Time for Third Quarter Fiscal 2024 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on July 31, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President &.

Cencora Announces Date and Time for Third Quarter Fiscal 2024 Earnings Release

3 Dividend Compounding Machines Poised for 30%+ Total Returns by 2026

Investors always praise compounder-type stocks, which are known for their proven ability to exponentially grow wealth over time. These companies usually achieve a high return on capital invested (ROCE) and return on equity (ROE).

3 Dividend Compounding Machines Poised for 30%+ Total Returns by 2026

Zacks Investment Research

Cencora (COR) Stock Nosedives: Here's What Caused the Decline

Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.

Cencora (COR) Stock Nosedives: Here's What Caused the Decline

Investors Business Daily

Drug Distributor Cencora Falls; Blame Walgreens, Not The Supreme Court

Cencora stock and other drug distributors fell on Wednesday, hit by Walgreens results, not the ruling that killed an opioid settlement.

Drug Distributor Cencora Falls; Blame Walgreens, Not The Supreme Court

Zacks Investment Research

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

Cencora: Long-Term Compounder With Mouth-Watering Economics

COR shares have advanced 13% since my last publication, adding conviction to the long-term thesis. The company has exceptional economic characteristics with abnormally high ROICs and negative working capital benefits. I have updated my price objectives to $270-$285 with a long-term intrinsic valuation of over $360 per share.

Cencora: Long-Term Compounder With Mouth-Watering Economics

See News Rankings